ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1448	National Cancer Institute	Html	en	Bladder and Other Urothelial Cancers Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for bladder cancer.	bladder cancers 0.459113 individual developing bladder 0.462762 bladder cancer patients 0.501836 Cancer Statistics Review 0.390961 transitional cell carcinoma 0.372436 American Cancer Society 0.389675 bladder cancer 0.911425 Bladder histological changes 0.431525 bladder cancer outcome 0.469139 bladder cancer cases 0.467655 Malignant bladder tumors 0.429947 bladder neoplasms 0.417201 bladder tumours 0.413309 repetitive hematuria screening 0.375531 bladder cancer risk 0.493294 bladder tumors 0.476533 superficial bladder cancer 0.470192 hematuria screening studies 0.380947 bladder toxicity 0.421878 Natl Cancer Inst 0.460204 newly diagnosed bladder 0.471386 Bladder Cancer Group 0.465328 metastatic bladder cancer 0.508614 neuropathic bladder 0.420139 et al. 0.424244	SEER Cancer Statistics 0.388904 bladder carcinogenesis 0.425543 bladder wall 0.415168 bladder cancer mortality 0.489217 bladder tumor antigen 0.4299 bladder cancer. 0.44027 urothelial bladder cancer 0.487451 Cancer Epidemiol Biomarkers 0.435283 urothelial cancer 0.372416 smoking related bladder 0.437945 PUBMED Abstract 0.468199 hematuria home screening 0.413339 bladder cancer case-fatality 0.488876 invasive bladder cancer 0.504621 Superficial bladder tumor 0.43348 National Cancer Institute 0.389198 Bladder cancer incidence 0.470999 bladder malignancies 0.448894 Epidemiol Biomarkers Prev 0.405245 bladder tumor incidence 0.430849 Bladder cancer screening 0.490371 Abstract 0.469966 recurrent bladder tumors 0.444789 urinary bladder cancer 0.487624	CLICK HERE
1544	National Cancer Institute	Html	en	Adult Acute Myeloid Leukemia Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of adult acute myeloid leukemia.	adult aml 0.716289 red blood cells 0.594071 cancer treatment 0.467513 blood -forming cells 0.4491 acute myeloblastic leukemia 0.44585 acute myelogenous leukemia 0.445245 chemotherapy 0.473847 PDQ cancer information 0.503817 white blood cells 0.675945 clinical trials 0.938073 mature blood cells 0.50039 cancer information summary 0.459101 clinical trial 0.615294 stem cells 0.519631 stem cell transplant 0.480735 acute granulocytic leukemia 0.446114 Myeloid Leukemia Treatment 0.448761 blood cells 0.735668 radiation therapy 0.468603 treatment 0.673705 myeloid stem cell 0.438755 stored stem cells 0.437216 immature blood cells 0.448693 arsenic trioxide 0.473356	cancer cells 0.602593 specific cancer cells 0.456728 recurrent adult aml 0.474546 untreated adult aml 0.465491 acute myeloid leukemia 0.930922 stem cell 0.533281 treatment clinical trials 0.44329 blood stem cells 0.488116 National Cancer Institute 0.460343 spinal cord 0.512703 normal cells 0.467456 myeloid stem cells 0.482174 new treatment 0.480473 white blood cell 0.463646 combination chemotherapy 0.472241 bone marrow 0.747056 cells 0.827248 acute promyelocytic leukemia 0.5928 cancer clinical trials 0.452604 acute nonlymphocytic leukemia 0.445812 acute lymphoblastic leukemia 0.434651 acute leukemia 0.43925 cancer 0.808047 standard treatment 0.467846	CLICK HERE
1872	National Cancer Institute	Html	es	Tratamiento del cáncer de células de transición de pelvis renal y de uréter (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del cáncer de células de transición de pelvis renal y de uréter.	Compton CC 0.310067 prognostic factors 0.311079 Roth BJ 0.353197 transitional cell carcinoma 0.558604 Sin embargo 0.332107 Ta Carcinoma 0.313126 Elson PJ 0.309122 California Oncology Group 0.314515 7th ed 0.310032 tumores renales 0.309511 pelvis renal 0.960657 Instituto Nacional 0.312591 metástasis distantes 0.32208 células transicionales recidivantes 0.361913 pared pélvica renal 0.316324 parénquima renal t3 0.317938 cooperative group study 0.316918 Cooperative Oncology Group 0.315511 tejido renal 0.313083 metastatic transitional cell 0.319135 preliminary report from 0.31524 group study 0.325781 Einhorn LH 0.327583 urinary tract 0.331593 función renal 0.325386	Northern California Oncology 0.31495 upper urinary tract 0.318654 effective chemotherapy regimen 0.317306 Oncology Group study 0.317114 Nocks BN 0.30983 Cancer Staging Manual 0.321607 PDQ Tratamiento 0.309071 Renal pelvic tumors 0.315825 New York 0.30907 Daly JJ 0.308968 with paclitaxel 0.310585 Clin Oncol 0.437926 parénquima renal 0.327814 Byrd DR 0.309554 urothelial carcinoma 0.398878 gallium combination chemotherapy 0.316792 insuficiencia renal 0.313531 Eastern Cooperative Oncology 0.315974 renal pelvis 0.422209 Oncology Group 0.324511 Tis Carcinoma 0.313191 metastatic urothelial carcinoma 0.363244 AJCC Cancer Staging 0.322547 Edge SB 0.31008	CLICK HERE
1941	National Cancer Institute	Html	es	La espiritualidad en el tratamiento del cáncer (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca de la influencia que tiene la espiritualidad y la religión en las personas que tienen cáncer. Se discuten varios métodos sobre manejo e intervención.	Illness Therapy—Spiritual Well-Being 0.364147 Koenig HG 0.516168 with breast 0.448622 with medical care 0.377932 Coping with breast 0.377717 among patients with 0.376638 religious involvement 0.469162 coping with 0.537521 religious coping 0.832653 longitudinal study 0.375646 Natl Med Assoc 0.392743 psychological distress 0.369731 Spillers RL 0.367074 palliative care consultation 0.388149 Sin embargo 0.391017 Psychiatry Med 0.42361 spiritual needs 0.450941 Balboni TA 0.366785 satisfaction with care 0.45185 among persons with 0.418188 patients with 0.768654 Religious Coping Scale 0.480675 Pargament KI 0.627933 Larson DB 0.403043 Tarakeshwar N 0.414441	Olver IN 0.377185 Care Cancer 0.680736 palliative care 0.405966 meet spiritual needs 0.420651 spiritual well-being among 0.364926 Vanderwerker LC 0.413553 mortality among medically 0.373039 spiritual well-being 0.567991 Consult Clin Psychol 0.378631 New York 0.37969 Intern Med 0.421384 Spiritual Intervention Study 0.363114 Palliat Med 0.935675 Clin Oncol 0.573043 Spiritual Well-Being Scale 0.362892 Cancer Surviv 0.366225 Arch Intern Med 0.39787 with metastatic breast 0.403978 spirituality as predictors 0.390155 spiritual care 0.472279 ill elderly patients 0.379545 chronic illness 0.365965 spiritual support among 0.431243 associations with 0.43557	CLICK HERE
1953	National Cancer Institute	Html	es	Efectos tardíos del tratamiento anticanceroso en la niñez (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de los problemas de salud que continúan o aparecen después de terminar un tratamiento de cáncer.	válvulas cardíacas 0.300344 digestivasLos efectos tardíos 0.301994 siguientes procedimientos 0.300445 células madre 0.31868 suficiente saliva 0.300202 adultos jóvenes 0.300215 tumor tipo 0.3006 leucemia linfocítica aguda 0.300977 leucemia linfoblástica aguda 0.303718 diabetes mellitus 0.300401 rayos x 0.300187 largo plazo 0.301433 alta densidad 0.300367 debilidad súbitos 0.300398 efectos tardíos 0.995697 luz solar 0.30049 tumores benignos 0.300573	siguientes maneras 0.300324 hormonas tiroideas 0.300415 antecedentes familiares 0.302575 revestimiento protector 0.300332 hepatitis b 0.300262 siguientes factores 0.300516 radiación uv 0.300991 topoisomerasa ii 0.300497 suficiente insulina 0.300239 cuerpo elabora insulina 0.300315 Radiografía panorámica 0.300213 leucemia mieloide aguda 0.302575 mandíbulasLos problemas 0.300385 cáncer infantil meses 0.303991 biliaresLos efectos tardíos 0.30194 Mayor tiempo 0.300312 siguientes pruebas 0.300654	CLICK HERE
1986	National Cancer Institute	Html	es	Linfedema (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos sobre la anatomía, la patofisiología, las manifestaciones clínicas, el diagnóstico y el tratamiento del linfedema relacionado con el cáncer, una afección en la que se acumula líquido linfático en los tejidos y causa inflamación..	after sentinel lymph 0.313822 Ridner SH 0.344357 group trial 0.315465 Sin embargo 0.344649 upper extremity lymphedema 0.331183 linfedema usa 0.380409 controlled trial with 0.318641 CA Cancer 0.317513 ganglios linfáticos centinelas 0.349529 arm lymphedema after 0.317881 extremity lymphedema after 0.335236 Cancer statistics 0.316994 treatment-related lymphedema 0.324253 lymphedema after breast 0.383555 ganglio centinela 0.352856 axillary sampling with 0.313496 conductos linfáticos subclavios 0.335825 Petrek JA 0.323456 Schmitz KH 0.339884 Sport Sci Rev 0.321461 controlled trial comparing 0.313482 randomized controlled 0.341872 Balancing lymphedema risk 0.334354 breast cancer-related lymphedema 0.386776 tronco linfático subclavio 0.332389	arm lymphedema 0.323652 axillary dissection with 0.315734 vena subclavia 0.3286 Care Cancer 0.334426 exercise versus deconditioning 0.326793 with axillary lymph 0.315505 ganglio linfático centinela 0.380935 with arm lymphedema 0.319809 Arch Phys Med 0.320628 discrepancia intramiembro 0.359416 Phys Med Rehabil 0.321125 breast carcinoma survivors 0.322235 lower-extremity lymphedema secondary 0.313534 with breast-cancer-related lymphedema 0.31752 Ahmed RL 0.322704 Clin Oncol 0.373772 breast cancer 0.91318 sentinel lymph 0.326667 Breast Cancer Study 0.332383 with or without 0.326647 Exerc Sport Sci 0.322466 axillary lymph 0.328084 Weight lifting 0.32136 Breast Cancer Res 0.331771	CLICK HERE
2030	National Cancer Institute	Html	es	Exámenes de detección del cáncer de seno (mama) (PDQ®)–Versión para profesionales de salud	Sumario de información revisada por expertos sobre pruebas que se usan para detectar el cáncer de mama.	carcinoma in situ 0.428206 Surgical Adjuvant Breast 0.33856 Breast Screening Study-2 0.364743 cohort with breast 0.321173 Breast Cancer Surveillance 0.36101 American Cancer Society 0.380459 ductal proliferative breast 0.324288 ductal carcinoma in 0.430875 breast biopsy 0.352636 Elmore JG 0.344418 Swedish two-county breast 0.320934 Breast Screening 0.503535 Breast Screening Study 0.375642 Rosenberg RD 0.33024 Kerlikowske K 0.327142 Nelson HD 0.325559 Canadian National Breast 0.417726 Individual Breast Biopsy 0.343511 evaluación bi-rads 0.320008 Scotia Breast Screening 0.356932 breast pathology 0.332437 Estados Unidos 0.485991 screening mammograms 0.346351 Natl Cancer Inst 0.674282 Breast tumor characteristics 0.346186	mamografía detecta 0.320239 breast self-examination 0.321577 screening mammographic sensitivity 0.338051 National Breast Screening 0.456899 mamografía digital versus 0.325297 Breast Screening Program 0.356597 modern screening mammography 0.338726 Cancer Facts 0.328174 breast cancers 0.931042 Image-detected breast 0.320721 Breast Imaging Reporting 0.320397 screening mammography 0.509779 Breast Biopsy Slides 0.344265 screening trial 0.341724 mammographic screening 0.329483 Carney PA 0.325142 Intern Med 0.487403 Breast symptoms among 0.322392 Arch Intern Med 0.323503 clinical breast 0.339712 mammographic screening from 0.319885 in situ 0.62536 Cancer Surveillance Consortium 0.332496 Nova Scotia Breast 0.339428	CLICK HERE
3422	National Cancer Institute	Html	es	Reconstrucción del seno después de una mastectomía	Hoja informativa que describe la reconstrucción del seno (mama) después de una mastectomía. Contiene información sobre las opciones quirúrgicas, los cuidados de seguimiento y los exámenes de detección del cáncer de seno después de la reconstrucción.	cirugía abdominal 0.39888 ley whcra 0.35286 Nipple-sparing mastectomy—is it 0.332063 Cordeiro PG 0.320216 colgajo siep 0.393996 Colgajo TRAM 0.39889 suficiente piel 0.387487 largo plazo 0.34858 large cell lymphoma 0.395571 reconstruction following surgery 0.356853 Reconstructive Surgery 0.417753 Colgajo SGAP 0.397479 Colgajo PAP 0.399861 Colgajo Latissimus 0.401399 PubMed Abstract 0.945047 Colgajo TUG 0.398937 colgajo diep 0.587224 Surgical Oncology Clinics 0.338406 Cirugía oncoplástica.  0.339864 La Cruz L 0.324776 NCI titulada Mamografías 0.32023 breast reconstruction 0.705756 colgajo igap 0.469394 pequeños trozos 0.3196 suficiente tejido 0.3777	colgajos ld 0.342761 Colgajo SIEA 0.398955 Da Lio A 0.329732 implantes de solución 0.348682 reconstruction after surgery 0.366752 therapy implications following 0.337385 suficiente volumen 0.324436 reconstrucción retardada 0.559365 Breast reconstruction after 0.445489 reconstruction after mastectomy 0.350953 Petit JY 0.31974 Breast Disease 0.377661 Cancer Rights Act 0.334748 Reviews Clinical Oncology 0.3359 oncoplastic breast-conserving surgery 0.341614 Total skin sparing 0.332343 técnica llamada 0.357673 sensibilidad conforme crecen y 0.339464 anaplastic large cell 0.394345 New England Journal 0.330568 ¿qué tipo 0.325566 physical therapy 0.407423 systematic reviews 0.354768 Surgical Oncology 0.355698	CLICK HERE
17190	National Cancer Institute	Html	en	Fertility Issues in Girls and Women with Cancer	Fertility issues are common in women getting cancer treatment. Fertility preservation options include egg freezing, embryo freezing, ovarian tissue freezing, ovarian shielding and ovarian transposition. Resources, support, and clinical trials are listed.	Sexual Health Issues 0.49945 cancer treatment 0.631654 fertility 0.901077 fertility option 0.589889 baseline fertility 0.607588 primary ovarian insufficiency 0.602729 health care team 0.580901 fertility problems 0.587938 stem cell transplants 0.556421 Child Health 0.492531 upsetting long-term effects 0.489052 nearby lymph nodes 0.481626 Bone marrow transplants 0.488319 fertility clinic 0.591948 nearby reproductive organs 0.498052 professionally led support 0.48644 fertility options 0.611153 Egg freezing 0.48771 female cancer patients 0.5846 radiation therapy 0.529983 hot flashes 0.502166 body receiving radiation 0.494041 menstrual periods 0.491262 vaginal dryness 0.507499 early-stage cervical cancer 0.50324	cancer treatments 0.607491 night sweats 0.503968 young female cancer 0.581679 ovaries 0.50886 embryo freezing 0.490634 blood stem cell 0.486791 personal health factors 0.498007 fertility return 0.579732 fertility preservation options 0.694907 fertility preservation 0.7168 ovarian shielding 0.508485 National Institute 0.498573 fertility risks 0.557024 Human Development 0.498529 Reproductive medical information 0.494403 LIVESTRONG Fertility 0.567758 fertility specialist 0.619863 Ovarian tissue freezing 0.511454 cancer 0.694555 fertility preservation clinic 0.610485 fertility preservation discounts 0.595763 ovarian tissue 0.520736 ovarian tissue cryopreservation 0.503109 nearby reproductive tissues 0.497596	CLICK HERE
17285	National Cancer Institute	Html	en	Cognitive Impairment in Adults with Non?Central Nervous System Cancers (PDQ®)–Health Professional Version	Expert-reviewed information summary about cognitive impairment in cancer patients versus normal cognition, and interventions to manage cognition changes	baseline cognitive reserve 0.507261 Cognitive changes 0.487133 adjuvant chemotherapy 0.565287 cancer treatment 0.487264 female breast cancer 0.505802 healthy control subjects 0.489493 Evidence-based cognitive rehabilitation 0.50091 Primary Breast Cancer 0.514885 Advanced cognitive training 0.507364 Clin Breast Cancer 0.579754 cognitive disturbance 0.483538 therapy-related cognitive deficits 0.504332 Eur J Cancer 0.484911 early-stage breast cancer 0.528107 cognitive dysfunction 0.521546 Von Ah 0.50591 cognitive function 0.609612 cancer-related cognitive impairment 0.500166 cognitive problems. 0.495567 breast cancer patients 0.582272 cancer patients 0.586019 elderly cancer patients 0.495074 cognitive functioning 0.510209 breast cancer survivors 0.779751 self-reported cognitive complaints 0.520137	cancer survivors 0.787075 cancer chemotherapy 0.497699 et al. 0.681052 psychosocial cancer rehabilitation 0.489752 colorectal cancer survivors 0.495325 cognitive rehabilitation 0.534264 PUBMED Abstract 0.565725 Support Care Cancer 0.521007 chemotherapy-treated breast cancer 0.517795 self-reported cognitive dysfunction 0.498525 experience cognitive problems 0.520232 cognitive impairment. 0.494247 Abstract 0.636513 Clin Oncol 0.48687 breast cancer 0.95028 group cognitive rehabilitation 0.514826 elderly cancer survivors 0.500464 randomized controlled trial 0.590229 Cognitive rehabilitation group 0.513937 treatment-related cognitive impairment 0.499304 brain tumor patients 0.525127 chemotherapy-related cognitive change 0.538912 cognitive impairment 0.555272 self-reported cognitive problems 0.505428	CLICK HERE